Managing just-in-time access at scale is a growing IAM challenge as speed and auditability collide daily. Tines shows how ...

Automating manual processes improves efficiency and eliminates human error. Learn about workflow automation and how to create ...

Dave Carlin has covered major national news stories and events in the past four decades including Superstorm Sandy and its tri-state impacts, Hurricane Hugo in South Carolina and Iniki on Kauai, ...

Lots of investors don’t recognize just how important the credit card company American Express is to Berkshire Hathaway. There was a time when Alphabet would have never even been allowed to become part ...

Tesla plans to begin Cybercab production in 2026, but it still needs key regulatory approvals for the vehicles to operate. The case for robotaxis is strong, but Tesla's autonomous vehicles may take ...

Nvidia Corp. (NASDAQ: NVDA) recently stopped testing whether it would manufacture its advanced artificial intelligence chips using Intel Corp.’s (NASDAQ: INTC) 18A production process, according to ...

BOSTON – There’s now a faster, more effective way to test new treatments for osteoporosis, and it is thanks in part to a decade-long effort led by Mary Bouxsein, PhD, a senior investigator in the ...

Temple and Belton school district board members put policy changes on paper the past two weeks, though officials in both districts have complied with the new requirements for months.

The Federal Reserve is seeking public comment on a new, limited “payment account” for crypto and innovation-focused banks. The accounts would allow access to Fed payment rails, but not interest, ...

Which of the statements below about the current US Food and Drug Administration (FDA)-approved biosimilars are correct? Select 1 option for each question, then submit your answers to see how well you ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min MediBeacon Inc., a St. Louis ...

The approval of subcutaneous amivantamab can offer a more accessible means of treatment for patients with non–small cell lung cancer (NSCLC). The subcutaneous approval for amivantamab is a significant ...